Previous studies have shown that TLR-2 and NOS-2 expression decreases with anti-inflammatory therapies and that the dysregulation or deletion of these genes is crucial for both IBD pathogenesis and attenuation of DSS induced colitis severity in mice [54,55,56,57]. The gene discussed is NOS2; the disease is inflammatory bowel disease.